Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nab-paclitaxel versus paclitaxel as neoadjuvant chemotherapy for HER2-negative breast cancer
ACTRN12613000119796Phase 3Completed
- Sponsor
- Michelangelo Foundation
- Start
- Aug 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial in breast cancer comparing Abraxane followed by anthracycline-containing chemotherapy with Paclitaxel followed by anthracycline-containing chemotherapy (2 arms). Primary endpoint: Pathological complete response. Started Aug 2013; status: completed.
02
Drugs
nab-paclitaxelpaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12613000119796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000119796.